StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CLDI yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $0.16 | $0.19 | +16.00% | 3.6M |
| 05-18 | $0.18 | $0.18 | +3.10% | 0.9M |
| 05-19 | $0.18 | $0.18 | +2.68% | 1.6M |
| 05-20 | $0.18 | $0.17 | -4.89% | 1.8M |
| 05-21 | $0.17 | $0.19 | +12.88% | 1.4M |
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 |
|---|---|---|
Revenue | $45.00K | $45.00K |
Operating Income | $-23.13M | $-18.44M |
Net Income | $-25.43M | $-17.67M |
EPS (Diluted) | $2.99 | $-2.08 |
Total Assets | $2.60M | $42.16M |
Total Liabilities | $43.44M | $10.37M |
Cash & Equivalents | $590.00K | $300.00K |
Free Cash Flow OCF − CapEx | $-13.64M | $-9.61M |
Shares Outstanding | 8.58M | 4.13M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.